For Q1 FY2024 (ended March 31, 2024), Oruka Therapeutics reported no revenue and a net loss of $31.82 million, a 51.5% increase from the prior year. Operating loss was $36.43 million, up 45.2% year-over-year. Diluted EPS was -$0.46, improving 93.4% from the prior year.
•Revenue was $0 for Q1 FY2024.
•Net loss widened to $31.82 million, up 51.5% year-over-year.
•Operating loss was $36.43 million, up 45.2% year-over-year.
•Diluted EPS improved to -$0.46, a 93.4% improvement year-over-year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and conditions.
It also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead product candidates include ORKA-001, which targets the p19 subunit of interleukin-23 and is in a Phase 2a trial for PsO, and ORKA-002, which targets interleukin-17A and interleukin-17F and is in a Phase 2 trial for PsO, psoriatic arthritis, and related conditions. The company is also developing ORKA-003 for an undisclosed pathway and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka is headquartered in Menlo Park, California.
Where is Oruka Therapeutics listed and what currency does it trade in?
Oruka Therapeutics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ORKA. Its shares trade in United States Dollars (USD). As a Nasdaq-listed company, Oruka is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission, providing transparency to investors. The company's listing on a major U.S. exchange facilitates liquidity and access for institutional and retail investors interested in the biotechnology sector.
What sector and industry does Oruka Therapeutics belong to?
Oruka Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it engages in the research and development of biologic drugs—in this case, monoclonal antibody therapeutics—for inflammatory and immunology indications. The company's focus on novel antibody treatments places it among clinical-stage biopharmaceutical firms that aim to address unmet medical needs in chronic inflammatory diseases like psoriasis and psoriatic arthritis.
Where is Oruka Therapeutics headquartered and what markets does it serve?
Oruka Therapeutics, Inc. is headquartered in Menlo Park, California, in the United States. The company primarily serves the U.S. market, as indicated by its country and region designation. Its clinical trials for lead candidates ORKA-001 and ORKA-002 are likely conducted in the U.S., targeting patients with psoriasis and other inflammatory conditions. While the company may eventually expand globally, its current operations and development activities are centered in the United States.
What are Oruka Therapeutics' main product candidates and their stages of development?
Oruka Therapeutics' pipeline includes several monoclonal antibody candidates. ORKA-001 targets the p19 subunit of interleukin-23 and is in a Phase 2a trial for psoriasis. ORKA-002 targets interleukin-17A and interleukin-17F and is in a Phase 2 trial for psoriasis, psoriatic arthritis, and related conditions. The company also has ORKA-003, which targets an undisclosed pathway, and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. All candidates are in clinical-stage development, with no approved products yet. The company focuses on inflammatory and immunology indications.